Actively Recruiting

Phase Not Applicable
Age: 20Years - 40Years
FEMALE
NCT06587698

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

Led by Peking University Third Hospital · Updated on 2024-09-19

300

Participants Needed

1

Research Sites

253 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research

CONDITIONS

Official Title

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

Who Can Participate

Age: 20Years - 40Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged 20-40 years planning to conceive or experiencing infertility
  • Diagnosed with PCOS based on Rotterdam criteria requiring two of the following: oligoovulation or anovulation, clinical or biochemical signs of hyperandrogenism, polycystic ovaries on ultrasound
  • Regularly followed at the clinic
  • No participation in other research projects currently or within the past 3 months
Not Eligible

You will not qualify if you...

  • Pregnant, lactating, or postmenopausal women
  • Use of weight loss medications or surgery in the past 3 months or currently
  • Food allergies
  • Other diseases causing hyperandrogenism or ovulation problems (e.g., Cushing's syndrome, adrenal or ovarian tumors, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency)
  • Use of insulin, hypoglycemic drugs, beta-blockers within past 3 months
  • Chronic diseases requiring regular medication (e.g., hypertension, gout, diabetes)
  • Use of glucocorticoids, anti-androgen drugs, oral contraceptives, ovulation-inducing drugs, weight loss drugs, or hormone-affecting medications in past 2 months
  • Severe liver or kidney disease
  • Severe cardiovascular or cerebrovascular diseases
  • Severe gastrointestinal diseases affecting nutrient absorption
  • Infectious diseases such as active tuberculosis, hepatitis B e antigen positive, or HIV
  • Cancer or recent radiation/chemotherapy within 5 years
  • Psychological or psychiatric disorders requiring medication
  • Daily alcohol consumption over 15g
  • Smoking habit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100000

Actively Recruiting

Loading map...

Research Team

J

Jie Qiao, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here